Condition (MeSH)
Dermatitis, Phototoxic
ClinicalTrials.gov lists 11 trials for Dermatitis, Phototoxic or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
11 of the 11 trials are tagged with Dermatitis, Phototoxic itself; the rest are tagged with a narrower condition beneath it.
When did Dermatitis, Phototoxic trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Not applicable
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2019 | 1 |
| 2016 | 1 |
| 2013 | 2 |
| 2010 | 2 |
| 2008 | 2 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 11 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Dermatitis, Phototoxic trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Not applicable | 3 |
How many Dermatitis, Phototoxic trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 10 |
| Withdrawn | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Dermatitis, Phototoxic trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bayer | 1 |
| Coria Laboratories, Ltd. | 1 |
| Healthpoint | 1 |
| Herbarium Laboratorio Botanico Ltda | 1 |
| MC2 Therapeutics | 1 |
Showing 5 of 10 sponsors.
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| MC2-01 Cream, irradiation | 1 |
| Vehicle Foam without irradiation | 1 |
| MC2-01 vehicle, no irradiation | 1 |
| Control, irradiation | 1 |
| No Treatment with UVA and UVB irradiation | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Dermatitis, Phototoxic? (10)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Protection against oxidative damage in human erythrocytes and preliminary photosafety assessment of Punica granatum seed oil nanoemulsions entrapping polyphenol-rich ethyl acetate fraction. | Toxicology in vitro : an international journal published in association with BIBRA | 2015 | Yes |
| A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2013 | Yes |
| Phototoxic and photoallergic potential of tazarotene foam 0.1% in 2 phase 1 patch studies. | Cutis | 2012 | Yes |
| Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial. | Photodermatology, photoimmunology & photomedicine | 2010 | Yes |
| Low risk of postinflammatory hyperpigmentation in skin types 4 and 5 after treatment with fractional CO2 laser device. | Journal of drugs in dermatology : JDD | 2008 | Yes |
Showing 5 of 10 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.